UCB’s ambition for patients relies on our ability to innovate and deliver highly differentiated medicines with unique outcomes. Today, following the recent acquisition of Handl Therapeutics BV, we are marking their full integration into the UCB family. This is great news as it advances our ability to develop novel treatments using state of the art gene therapy technology.
UCB has a vision to move from symptomatic treatments to disease modification and eventually towards a cure. Adeno-associated virus (AAV) mediated gene therapy offers to deliver that potential and drive a fundamental change in how diseases are treated with the ability to remove or add disease-related proteins with a single treatment. A vast array of severe diseases are amenable to gene therapy and UCB is embracing this modality to expand its capabilities and ultimately transform the lives of patients with severe diseases.
Handl Therapeutics BV is a Leuven-based, Belgium born, transformative gene therapy company with a vision to deploy the power of disease modifying in vivo gene therapy to treat complex neurodegenerative diseases. Operating in a highly collaborative manner, the company built a strong international network to access global capabilities and expertise. To this end, it combines state of the art technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK) to address unmet medical needs.
Over the past 90 years, we have been on an incredible journey to become the company you see today. We’ve evolved and adapted but always looked to innovate and deliver highly differentiated medicines.
by Luc Uylenbroeck, UCB
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.